| TA182 |
Acute coronary syndrome - prasugrel (TA182) |
|
-
-
Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention
Prasugrel in combination with aspirin is recommended as an option for preventing blockages in the arteries of people with acute coronary syndromes who are having a treatment called percutaneous coronary intervention only when:
- immediate percutaneous coronary intervention is necessary to treat an ST-segment-elevation myocardial infarction (a type of heart attack) or
- a blood clot has blocked a stent (a small mesh-like tube inserted into an artery to keep it open) during treatment with a drug called clopidogrel or
- the patient has diabetes mellitus.
Healthcare professionals should not stop prescribing prasugrel for people who were already taking it when the guidance was issued. These people should be able to carry on taking prasugrel until they and their healthcare professionals decide that it is the right time to stop treatment.
-
Other information
How this guidance was produced
Background information
This page was last updated: 12 December 2011
-
Guidance formats
-
Implementation tools and resources
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
